Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD06-04 Anti-CD19 CAR-T Cell Therapy in Moderate to Severe Active SLE
NCT06310811Phase 1Suspended
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RD06-04 in systemic lupus erythematosus (SLE). Primary endpoints: Incidence of dose-limiting toxicity at 28 days, Incidence of treatment-emergent adverse events at 3 months and 1 more. Started Mar 2024; status: suspended.
02
Drugs
RD06-04
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06310811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06310811.